Boccardo F et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 2005;23(22):5138-47. Abstract

Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Proc SABCS 2003;Abstract 3.

Boccardo F et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study. J Clin Oncol 2001;19(22):4209-15. Abstract

Coombes RC et al; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract

Duffy SR et al. Gynecologic interventions during adjuvant therapy with anastrozole or tamoxifen: Results from the ATAC trial. San Antonio Breast Cancer Symposium 2005;Abstract 2056.

Goss PE et al. NCIC CTG MA17: Disease free survival according to estrogen receptor and progesterone receptor status of the primary tumor. San Antonio Breast Cancer Symposium 2005;Abstract 2042.

Goss PE et al. Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding. San Antonio Breast Cancer Symposium 2005;Abstract 16.

Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract

Howell A et al. Results of the ATAC (Anastrozole, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Ingle JN et al. Analysis of duration of letrozole extended adjuvant therapy as measured by hazard ratios of disease recurrence over time for patients on NCIC CTG MA.17. San Antonio Breast Cancer Symposium 2005;Abstract 17.

Jakesz R, on behalf of the ABCSG. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). Proc ASCO 2005a;Abstract 527.

Jakesz R et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005b;366(9484):455-62. Abstract

Jakesz R, on behalf of the ABCSG. Benefits of switching postmenopausal women with hormone sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Presentation. San Antonio Breast Cancer Symposium 2004;Abstract 2.

Jonat W et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: A meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial. San Antonio Breast Cancer Symposium 2005;Abstract 18.

Saphner T et al. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14(10):2738-46. Abstract

Thürlimann B for the BIG 1-98 Collaborative Group. Letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. First results of IBCSG 18-98/ BIG 1-98. Presentation. St Gallen Breast Cancer Conference 2005. Breast 2005a;14(Suppl 1):3;S4.

Thürlimann BJ et al. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Presentation. ASCO 2005b;Abstract 511.

Viale G et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 44.